Merrill Birkner

Title: Merrill Birkner: Innovator in Cancer Treatment

Introduction

Merrill Birkner is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, Birkner's work focuses on improving patient outcomes in oncology.

Latest Patents

Birkner's latest patents include groundbreaking methods for predicting responses to HER inhibitors. The first patent describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also outlines the use of a high HER2:HER3 ratio as a selection criterion for treating cancer patients, particularly those with ovarian cancer. Additionally, the application discusses the use of high HER3 as a selection criterion for treating cancer patients with chemotherapeutic agents, such as gemcitabine.

Career Highlights

Throughout his career, Birkner has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and Hoffmann-La Roche Inc. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.

Collaborations

Birkner has collaborated with notable colleagues, including Lukas C. Amler and Chin-Yu Lin. These partnerships have further enhanced his research and development efforts in the field of oncology.

Conclusion

Merrill Birkner's contributions to cancer treatment through his patents and collaborations highlight his commitment to improving patient care. His innovative approaches continue to influence the landscape of cancer therapy.